dc.contributor.author |
McColl, BW |
en |
dc.contributor.author |
McGregor, Ailsa |
en |
dc.contributor.author |
Wong, A |
en |
dc.contributor.author |
Harris, JD |
en |
dc.contributor.author |
Amalfitano, A |
en |
dc.contributor.author |
Magnoni, S |
en |
dc.contributor.author |
Baker, AH |
en |
dc.contributor.author |
Dickson, G |
en |
dc.contributor.author |
Horsburgh, K |
en |
dc.date.accessioned |
2012-03-06T01:01:56Z |
en |
dc.date.issued |
2006 |
en |
dc.identifier.citation |
J Cereb Blood Flow Metab 27(3):477-487 Mar 2007 |
en |
dc.identifier.issn |
0271-678X |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/13030 |
en |
dc.description.abstract |
Apolipoprotein E (apoE, protein; APOE, gene) is the major lipid-transport protein in the brain and plays an important role in modulating the outcome and regenerative processes after acute brain injury. The aim of the present study was to determine if gene transfer of the 3 form of APOE improves outcome in a murine model of transient focal cerebral ischaemia. Mice received an intrastriatal injection of vehicle, a second-generation adenoviral vector containing the green fluorescent protein gene (Ad-GFP) or a vector containing the APOE 3 gene (Ad-APOE) 3 days before 60 mins focal ischaemia. Green fluorescent protein expression was observed in cells throughout the striatum and subcortical white matter indicating successful gene transfer and expression. ApoE levels in the brain were significantly increased after Ad-APOE compared with Ad-GFP or vehicle treatment. Ad-APOE treatment reduced the volume of ischaemic damage by 50% compared with Ad-GFP or vehicle treatment (133 versus 294 versus 275 mm3). The extent of postischaemic apoE immunoreactivity was enhanced in Ad-APOE compared with Ad-GFP or vehicle treated mice. These results show the ability of APOE gene transfer to markedly improve outcome after cerebral ischaemia and suggest that modulating apoE levels may be a potential strategy in human stroke therapy. |
en |
dc.description.uri |
http://www.nature.com/jcbfm/journal/vaop/ncurrent/abs/9600361a.html;jsessionid=8C21CA0FC458CAEE5300A3D4280DB375 |
en |
dc.publisher |
Nature Publishing Group |
en |
dc.relation.ispartofseries |
Journal of Cerebral Blood Flow and Metabolism |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0271-678X/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
APOE varepsilon 3 gene transfer attenuates brain damage after experimental stroke |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1038/sj.jcbfm.9600361 |
en |
pubs.issue |
3 |
en |
pubs.begin-page |
477 |
en |
pubs.volume |
27 |
en |
dc.rights.holder |
Copyright: Nature Publishing Group |
en |
dc.identifier.pmid |
16804548 |
en |
pubs.end-page |
487 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
66997 |
en |
pubs.record-created-at-source-date |
2010-09-01 |
en |
pubs.dimensions-id |
16804548 |
en |